Hepatocellular Carcinoma Articles & Analysis
37 news found
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] PreHevbri is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, ...
This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbrio™ VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About VBI’s 3-Antigen HBV Vaccine VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed for the treatment of ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbri VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] / PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the ...
“Senti Bio’s use of Logic Gated gene circuits in its off-the-shelf CAR-NK designs has the potential to selectively target tumors while sparing healthy cells and, I believe, expand the cell therapy opportunity to additional tumor types including acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer and others. I am also drawn to the broad ...
“This year's ASGCT presentations mark significant progress across our pipeline of allogeneic gene circuit-enabled CAR-NK cell product candidates, particularly for our two lead programs in acute myeloid leukemia and hepatocellular carcinoma,” said Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. ...
Data from this presentation demonstrate that Senti Bio’s CAR-NK cell manufacturing process will likely support translation to GMP clinical manufacturing in support of multiple allogeneic CAR-NK cell therapy products across the Company’s pipeline, including planned clinical development of SENTI-202 for acute myeloid leukemia and SENTI-301 for hepatocellular ...
The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC). Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, effectiveness, and ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...
Senti Bio’s gene circuit technology is being applied in the design of multiple product candidates including SENTI-202 for the potential treatment of acute myeloid leukemia (AML), SENTI-301 for the potential treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the potential treatment of colorectal cancer (CRC). ...
” Ten embolizations were performed in 8 patients with a range of tumor types, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and angiomyolipoma (AML). ...
This technology is being applied in the design of multiple Senti Bio pipeline products including SENTI-301 and SENTI-401, which are aimed to treat solid tumors such as hepatocellular carcinoma (HCC) and colorectal cancer (CRC) respectively. ...
” Topline Efficacy and Safety Data Poster Title: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients (Abstract #462 / Poster: M10) The Company will present topline data for cohort A of the DEDUCTIVE study, which is assessing the ...
” Full List of Guardant Health Presentations: Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01 (Abstract 168) Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...